Graph Pipeline


Expanding Innovative Pipeline of Cancer Metabolism-Based Compounds (CMBTsTM)

SM-88 (D,L-alpha-metyrosine; racemetyrosine [USAN]) is a first-in-class investigational agent in Phase II development for pancreatic and prostate cancer. SM-88 is used with three other drugs: methoxsalen, phenytoin, and sirolimus (hereafter, referred to as SM-88 used with MPS). 

SM-88 has shown complete and partial responses across 15 different cancer types, including some of the most common and hard to treat cancer types, such as pancreatic, prostate, breast, lung, glioma, ovarian, Ewing’s sarcoma, sarcoma and colon cancer.

Patented formulations include the combination of SM-88 with other therapeutic classes intended to specifically destabilize the cancer cells. SM-88 is the core component of SM-88 used with MPS and is believed to disrupt protein synthesis in the cancer cells, and ultimately lead to apoptosis.

MOA Backgrounder

(View PDF)